Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Colgate-Palmolive

Enterprise Products Partners

Gladstone Investment

Interpublic Group of Companies

Lockheed Martin

LTC Properties

Main Street Capital

MetLife

Merck

People's United Financial

iShares Preferred and Income Securities ETF 

Prudential Financial

Shaw Communications

STAG Industrial

Unum

Verizon

Exxon Mobil

From May to December 2020, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. Those five "outstanding dividend" articles revealed 56 equities. Kiplinger article titles were, 'Dividend15: Our Favorites'; '15 Super-Safe Dividends'; '7 Durable Distributions'; '13 100+Year Dividends'; '11 Monthly-Pay Stocks/Funds.'

Kiplinger Outstanding August Dividend Dogs Feature 9 Primed To Buy

Abbvie - Still Undervalued With More Room To Grow

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2021 Results - Earnings Call Transcript

AbbVie (ABBV) matches second-quarter 2021 earnings estimates while beating the same for sales. Sales of new immunology drugs, Skyrizi and Rinvoq, reach $1 billion.

AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised

AbbVie (ABBV) delivered earnings and revenue surprises of 0.00% and 1.81%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q2 Earnings Match Estimates

Pfizer

These two companies offer impressive -- and safe -- yields for investors who like income.

Have $500? Here Are 2 High-Yielding Healthcare Stocks to Consider

AbbVie Inc (NYSE: ABBV) reports Q2 adjusted EPS of $3.11, marginally beating the consensus of $3.09. Overall sales increased 33.9% Y/Y to $13.9 billion, slightly ahead of the consensus of $13.6 billion.

AbbVie Q2 Earnings Beats Consensus Slightly; Guides FY21 EPS Below Consensus

AbbVie Inc. beat expectations for the second quarter of 2021, driven largely by gains in its immunology business. The drug maker had earnings of $766 million, or 42 cents per share, in the second quarter of 2021.

AbbVie cites growth of immunology business in the second quarter

Shares of AbbVie (NYSE:ABBV) decreased 0.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 32.91% over the past year to $3.11, which beat the estimate of $3.09.

Recap: AbbVie Q2 Earnings

Drugmaker AbbVie Inc raised its full-year adjusted profit forecast on Friday, as demand soared for its Botox anti-wrinkle injection in the second quarter following the easing of COVID-19 restrictions.

AbbVie raises annual profit forecast as Botox demand rebounds

NORTH CHICAGO, Ill., July 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2021.

AbbVie Reports Second-Quarter 2021 Financial Results

Enbridge

Philip Morris

TC Energy

5 Blue-Chip Bargains That Create The World's Safest 6% Yielding Retirement Portfolio

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy AbbVie (ABBV) Ahead of Earnings?

Venclexta's potential indication for the treatment of myelodysplastic syndrome could mean billions for AbbVie this decade.

How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market

Netflix

These two companies will be excellent buys in the event of another coronavirus-fueled market crash.

Market Crash 2.0: Where to Invest $1,000

NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of BOTOX® to include eight new muscles for the treatment of upper limb spasticity in adults.

FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity

MercadoLibre

Cryptomania isn't all it's cracked up to be.

Thinking About Joining the Dogecoin Craze? Here are 2 Smarter Buys

Cummins

Let's explore two blue chip stocks that investors might want to consider buying as they report Q2 earnings.

2 Blue Chip Stocks to Buy Before Earnings and Hold for Years

AbbVie Inc (NYSE: ABBV) and Calico Life Sciences have collaborated to discover and develop new therapies for patients with age-related diseases, including neurodegeneration and cancer.  It is the second extension of the collaboration initially established in 2014.

AbbVie, Alphabet-Founded Calico Extends Collaboration Focused on Aging, Age-Related Diseases

AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and… The post AbbVie Inc. (ABBV) and Calico Announce Second Extension of Collaboration appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

AbbVie Inc. (ABBV) and Calico Announce Second Extension of Collaboration

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif.

AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases

Chevron

LyondellBasell Industries

Time and time again, the Wall Street pundits say interest rates are going higher, and time and time again they plunge lower.

S&P 500 Dividend Yield Lowest in 20 Years: 5 Blue Chips to Buy Now With Huge Dividends

NORTH CHICAGO, Ill., July 25, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition

News for AbbVie Stock (ABBV)